GSK (GSK) wins US approval for Hibsago in chronic hepatitis B
The bepirovirsen approval creates a new treatment option for a defined group of adults already receiving antiviral therapy.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
GSK has secured FDA approval for Hibsago, its antisense medicine bepirovirsen, in chronic hepatitis B. The treatment is used with nucleos(t)ide analogue therapy in adults without cirrhosis who meet specified virological criteria.
The label matters as much as the headline. Patients must have received their existing antiviral treatment for at least six months, have suppressed hepatitis B DNA and have surface-antigen levels no higher than 3,000 IU/ml, measured using an authorised test. This is not an unrestricted approval for everyone living with hepatitis B.
GSK describes a six-month course, with self-administration possible after the first dose. The decision strengthens its infectious-disease portfolio and creates a commercial opportunity around a finite treatment regimen.
The company's functional-cure positioning should be understood within the trial definitions and approved population. It does not mean universal viral eradication. Uptake will depend on identifying eligible patients, specialist confidence and access arrangements, alongside the medicine's clinical performance in routine practice.